SS-31 (10 mg Vial) Research Protocol

SS-31 Research Information

SS-31 is commonly studied at 5–10 mg daily using subcutaneous administration in educational research protocols. A 10 mg vial reconstituted with bacteriostatic water yields approximately 10 mg/mL. This information is provided for research and educational purposes only.

SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane[1], helping support electron transport chain function while reducing reactive oxygen species production and supporting ATP synthesis[2]. It has been investigated in preclinical models of heart failure, neurodegenerative disease, and age-related muscle atrophy, and received FDA accelerated approval in 2025 for Barth syndrome[3]. This educational research protocol presents a once-daily subcutaneous administration approach using a concentrated reconstitution for practical insulin syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read SS-31 Peptide: Benefits, Uses, Side Effects, and Research Information.

Educational guide for reconstitution and daily research administration.

Standard Research Approach (1 mL = 10 mg/mL)

Week	Daily Anount	Old Units	New Units
Weeks 1–2	200 µg	12 units (0.12 mL)	6 units (0.06 mL)
Weeks 3–4	300 µg	18 units (0.18 mL)	9 units (0.09 mL)
Weeks 5–6	400 µg	24 units (0.24 mL)	12 units (0.12 mL)
Weeks 7–8	500 µg	30 units (0.30 mL)	15 units (0.15 mL)

Frequency: Administer once daily by subcutaneous administration at a consistent time. This concentrated reconstitution (1.0 mL per 10 mg vial) keeps standard research amounts within a single insulin syringe for convenient and accurate measurement.

Reconstitution Steps

1. Draw 1.0 mL bacteriostatic water with a sterile syringe.
2. Slowly add the bacteriostatic water down the inside wall of the vial. Avoid vigorous shaking to prevent foaming.
3. Gently swirl or roll the vial until the contents are fully dissolved and the solution is clear.
4. Label the vial with the reconstitution date and store at 2–8 °C (35.6–46.4 °F), protected from light. Use within 4 weeks.

Advanced Research Approach (1 mL = 10 mg/mL)

Week	Daily Anount	Old Units	New Units
Weeks 1–2	200 µg	12 units (0.12 mL)	6 units (0.06 mL)
Weeks 3–4	300 µg	18 units (0.18 mL)	9 units (0.09 mL)
Weeks 5–6	400 µg	24 units (0.24 mL)	12 units (0.12 mL)
Weeks 7–8	500 µg	30 units (0.30 mL)	15 units (0.15 mL)

Note: Higher research amounts (15–20 mg/day) have been evaluated in limited short-term clinical research for severe mitochondrial conditions[4][5]. Research amounts above 10 mg require two separate subcutaneous administrations at different sites. Clinical studies have not extensively evaluated SS-31 beyond 12 weeks, so longer research periods require appropriate monitoring.

Important: This guide is provided for research and educational purposes only and does not constitute medical advice. SS-31 is intended for research use only and is not intended for human consumption.

Plan based on an 8–12 week daily research protocol with a gradual approach.

Concise summary of the once-daily subcutaneous regimen.

Goal: Support mitochondrial function, enhance ATP production, and reduce oxidative stress in tissues with high metabolic demand.
Schedule: Daily subcutaneous administration for 8–12 weeks (clinical trials typically 4–12 weeks).
Research Range: 5–10 mg daily (standard); 15–20 mg daily (advanced, under supervision).
Reconstitution: 1.0 mL per 10 mg vial (10 mg/mL) for convenient single-device administration.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 4 weeks.

Suggested daily titration approach based on clinical trial protocols.

Start: 5 mg daily for Weeks 1–2 to assess individual tolerance.
Standard Target: 10 mg daily by Week 3 (most common clinical trial dose).
Advanced Target: 15–20 mg daily for Weeks 5+ (only for severe conditions under medical oversight).
Frequency: Once per day (subcutaneous administration); maintain consistent timing.
Cycle Length: 8–12 weeks; limited data exists beyond 12 weeks.
Timing: Any consistent time; rotate application sites to prevent tissue irritation.

Proper storage preserves peptide stability and potency.

Lyophilized: Store at −20 °C (−4 °F) in original sealed vial; keep dry and protected from light. Stable for months when frozen.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing; use within 4 weeks for optimal stability.
Avoid freeze–thaw: Do not refreeze reconstituted solution; prepare aliquots if needed to minimize temperature fluctuations.
Allow refrigerated vials to reach room temperature before opening to reduce condensation inside the vial.

Practical considerations for consistency, safety, and tolerability.

Use new sterile measuring devices for each administration; dispose according to local laboratory or institutional guidelines.
Rotate application sites systematically (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy.
Administer slowly over several seconds; wait briefly before completing the administration to minimize leakage.
Mild application-site reactions (redness, itching, transient discomfort) are the most common side effects reported in clinical trials; these typically resolve within hours.
Document daily amount, application site, and any adverse reactions to maintain consistency and identify patterns.
For amounts requiring split administrations (≥15 mg), space administrations at least 2 inches apart on different body regions.

SS-31 (elamipretide) is a cell-permeable tetrapeptide with a unique mechanism of action targeting mitochondrial dysfunction. The peptide selectively accumulates in the inner mitochondrial membrane where it binds to cardiolipin, a specialized phospholipid essential for organizing electron transport chain supercomplexes and maintaining cristae structure. By stabilizing cardiolipin-protein interactions, SS-31 optimizes electron transport efficiency, reduces pathological reactive oxygen species generation, and enhances ATP synthesis in metabolically active tissues.

Preclinical research demonstrated that SS-31 protects against mitochondrial dysfunction across multiple disease models including heart failure, ischemia-reperfusion injury, neurodegeneration, chronic kidney disease, and age-related muscle atrophy. In human clinical trials, SS-31 showed favorable safety and tolerability profiles with no dose-limiting toxicities. While Phase II trials in heart failure and primary mitochondrial myopathy did not meet primary efficacy endpoints, the TAZPOWER trial in Barth syndrome demonstrated significant improvements in muscle strength and six-minute walk distance, leading to FDA accelerated approval in 2025.

Observations from preclinical models and human clinical trials.

Stabilizes mitochondrial membranes and optimizes electron transport chain function.
Enhances ATP production and reduces pathological reactive oxygen species in metabolically active tissues.
Demonstrated functional improvements in Barth syndrome patients (increased muscle strength, improved exercise capacity).
Shows protective effects in preclinical models of heart failure, neurodegenerative disease, and age-related muscle atrophy.
Does not significantly alter blood pressure, heart rate, or standard laboratory parameters in clinical trials.
Application-site reactions (most common): Mild-to-moderate redness, itching, or transient discomfort at the application site; typically resolves within hours.
Approximately 80% of patients in clinical trials experienced mild application-site reactions.
No dose-limiting toxicities or serious adverse events directly attributed to SS-31 in published trials.
Long-term safety data beyond 12 weeks remains limited; extended use requires monitoring.

Complementary strategies to support mitochondrial health and optimize outcomes.

Nutrition: Emphasize mitochondrial cofactors including B-vitamins, CoQ10, magnesium, and alpha-lipoic acid; maintain adequate protein intake to support muscle maintenance.
Exercise: Combine resistance training with aerobic activity to stimulate mitochondrial biogenesis and enhance oxidative capacity; tailor intensity to individual tolerance.
Sleep: Prioritize 7–9 hours of quality sleep to support cellular repair processes and optimize mitochondrial turnover through autophagy.
Stress Management: Chronic stress increases oxidative burden; incorporate stress-reduction practices such as meditation, breathwork, or yoga.
Avoid Mitotoxins: Minimize exposure to substances that impair mitochondrial function, including excessive alcohol, certain medications (when possible), and environmental toxins.

General subcutaneous administration guidance from clinical best-practice resources.

Site Preparation: Clean the vial stopper and application site with alcohol swabs; allow to air-dry completely (30–60 seconds) before proceeding.
Preparing the Amount: Use a new sterile measuring device for each administration; prepare the required volume from the refrigerated vial; remove any visible air bubbles by gently tapping the measuring device.
Administration Angle: Pinch a fold of skin (approximately 1–2 inches); insert at 45–90° depending on subcutaneous tissue thickness (90° for most adults; 45° if very lean).
Administration: Do not aspirate for subcutaneous administration; administer slowly and steadily over 3–5 seconds; wait 5–10 seconds before completing the administration to minimize leakage.
Site Rotation: Rotate systematically between application sites (abdomen at least 2 inches from navel, outer thighs, upper arms, upper buttocks) to prevent lipohypertrophy and local irritation.
Post-Administration: Apply gentle pressure with a clean alcohol swab or cotton ball for a few seconds; do not massage the site vigorously. A small bandage may be applied if needed.
Disposal: Immediately dispose of used measuring devices according to local laboratory or institutional guidelines.

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. SS-31 is currently FDA-approved only for Barth syndrome under the brand name Forzinity; use for other conditions remains investigational. Always consult with qualified healthcare professionals before beginning any peptide protocol. This information is provided for research and educational purposes only.

The following information provides general educational context related to scientific discussions and available background materials.

International Journal of Molecular Sciences (MDPI)

— Elamipretide: comprehensive review of structure, mechanism of action, and therapeutic potential

British Journal of Pharmacology (PMC)

— Cardiolipin-binding mechanism and mitochondrial membrane stabilization by SS-31

U.S. Food & Drug Administration (FDA)

— FDA grants accelerated approval to elamipretide (Forzinity) as first treatment for Barth syndrome (2025)

Journal of the American College of Cardiology (JACC)

— PROGRESS-HF trial: safety and tolerability of elamipretide in heart failure patients

Neurology (AAN Journals)

— MMPOWER-2 trial: elamipretide in primary mitochondrial myopathy.

Genetics in Medicine (Nature)

— TAZPOWER trial: efficacy and safety of elamipretide in Barth syndrome

Biochimica et Biophysica Acta (BBA) – Bioenergetics

— Cardiolipin remodeling and cristae structure: role in mitochondrial function

Journal of Cardiovascular Pharmacology (PMC)

— SS-31 reduces oxidative stress and improves mitochondrial bioenergetics

Alzheimer's Drug Discovery Foundation

— Cognitive Vitality Report: SS-31 (elamipretide) preclinical and clinical overview

Orphanet Journal of Rare Diseases (PMC)

— Barth syndrome: clinical presentation, diagnosis, and emerging therapies

Centers for Disease Control and Prevention (CDC)

— Vaccine administration: subcutaneous administration technique (angle, site selection, no aspiration)

Johns Hopkins Arthritis Center

— Patient guide: how to perform subcutaneous administration (step-by-step instructions)

NCBI Bookshelf (StatPearls)

— Best practices for administration: aseptic technique, preparation, and administration

Pharmacologic Considerations of Subcutaneous Drug Administration (PMC)

— Site rotation, absorption kinetics, and prevention of lipohypertrophy